Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events ‐ hypokalaemia · children with severe dehydration due to diarrhoea
Balanced crystalloid solutions probably leads to lower adverse events: hypokalaemia compared with 0.9% saline (moderate certainty).
1 finding from 1 review
RR 0.54 [0.31, 0.96]
Studies not reported
Moderate
Adverse events ‐ Miscarriage · patients with male subfertility
It is very uncertain whether antioxidants changes adverse events ‐ Miscarriage compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events ‐ infection ( · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in adverse events ‐ infection ( compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade I or II adverse events compared with BCG (very low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade I or II adverse events compared with saline (low certainty).
1 finding from 1 review
Occurrence of adverse events · cancer cachexia in adults
It is very uncertain whether multimodal intervention (exercise plus other interventions) plus… changes occurrence of adverse events compared with usual care (very low certainty).
1 finding from 1 review
Occurrence of adverse events · cancer cachexia in adults
1 finding from 1 review
Adverse events ‐ pelvic pain · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ pelvic pain compared with placebo (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review